Preclinical Assessment of Young Blood Plasma for Alzheimer Disease.

ABSTRACT:

Importance

Alzheimer disease (AD) pathology starts long before clinical symptoms manifest, and there is no therapy to treat, delay, or prevent the disease. A shared blood circulation between 2 mice (aka parabiosis) or repeated injections of young blood plasma (plasma from 2- to 3-month-old mice) into old mice has revealed benefits of young plasma on synaptic function and behavior. However, to our knowledge, the potential benefit of young blood has not been tested in preclinical models of neurodegeneration or AD.

Objectives

To determine whether young blood plasma ameliorates pathology and cognition in a mouse model for AD and could be a possible future treatment for the disease.

Design, setting, and participants

In this preclinical study, mice that harbor a human mutan

SUBMITTER: Middeldorp J 

PROVIDER: S-EPMC5172595 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature